Related Experiment Video

Updated: Apr 20, 2026

Electrocardiogram Recordings in Anesthetized Mice using Lead II
04:16

Electrocardiogram Recordings in Anesthetized Mice using Lead II

Published on: June 20, 2020

14.9K

Life-Threatening QT Prolongation in a Preterm Infant

Christian Paech1, Roman Gebauer1, Matthias Knüpfer2

  • 1Department for Pediatric Cardiology, University of Leipzig - Heart Center, Leipzig, Germany.

AJP Reports
|December 3, 2014
PubMed

Insights

Congenital hydrocephalus can cause dangerous heart rhythm problems in preterm infants, leading to excessive QT prolongation and bradycardia. This condition requires careful monitoring in newborns with hydrocephalus.

Area of Science:

  • Pediatric Cardiology
  • Neonatology
  • Neurology

Background:

  • QT interval prolongation is a known complication of intracranial hemorrhage and hydrocephalus in adults.
  • Congenital hydrocephalus is a condition characterized by excessive cerebrospinal fluid accumulation in the brain.

Observation:

  • A preterm infant with congenital hydrocephalus experienced excessive QT prolongation.
  • This was associated with sudden bradycardia and 2:1 atrioventricular conduction.
  • The event suggests a link between congenital hydrocephalus and cardiac arrhythmias in neonates.

Findings:

  • Congenital hydrocephalus appears to be a predisposing factor for excessive QT prolongation in preterm infants.
  • The case highlights potential pathomechanisms linking neurological conditions to cardiac events in neonates.
  • Sudden bradycardia and conduction abnormalities can occur secondary to QT prolongation.

Implications:

  • Neonates with congenital hydrocephalus require vigilant cardiac monitoring for QT interval prolongation and arrhythmias.
  • Understanding these associations can improve the management of preterm infants with neurological and cardiac comorbidities.
  • Further research into the pathomechanisms is warranted to develop targeted preventative strategies.

Keywords:
aqueductal stenosishydrocephaluslong QTpreterm

More Related Videos

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

18.3K
Preterm EEG: A Multimodal Neurophysiological Protocol19:32

Preterm EEG: A Multimodal Neurophysiological Protocol

Published on: February 18, 2012

29.2K

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
3.0K
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
1.1K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
513
Cardiac Action Potential01:30

Cardiac Action Potential

Cardiac action potentials are essential for proper heart function, enabling the rhythmic contractions needed for adequate blood circulation. Nodal cells and Purkinje fibers, specialized for electrical conduction, generate these action potentials.
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials
11.6K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
895
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration01:23

Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration

Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s...
118